133 related articles for article (PubMed ID: 38727992)
1. Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study.
Tran Van Hoi E; Trompet S; Van Holstein Y; Van Den Bos F; Van Heemst D; Codrington H; Labots G; Lohman S; Ozkan A; Portielje J; Mooijaart SP; De Glas NA; Derks M
Drugs Aging; 2024 May; 41(5):431-441. PubMed ID: 38727992
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper.
Guven DC; Martinez-Cannon BA; Testa GD; Martins JC; Velasco RN; Kalsi T; Gomes F
J Geriatr Oncol; 2024 May; 15(4):101742. PubMed ID: 38472009
[TBL] [Abstract][Full Text] [Related]
3. Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic review.
Özkan A; van den Bos F; Mooijaart SP; Slingerland M; Kapiteijn E; de Miranda NFCC; Portielje JEA; de Glas NA
Crit Rev Oncol Hematol; 2024 Feb; 194():104259. PubMed ID: 38199430
[TBL] [Abstract][Full Text] [Related]
4. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
Olsson Ladjevardi C; Koliadi A; Rydén V; Inan El-Naggar A; Digkas E; Valachis A; Ullenhag GJ
Cancer Med; 2023 Jun; 12(12):13217-13224. PubMed ID: 37132258
[TBL] [Abstract][Full Text] [Related]
5. Frailty and checkpoint inhibitor toxicity in older patients with melanoma.
Bruijnen CP; Koldenhof JJ; Verheijden RJ; van den Bos F; Emmelot-Vonk MH; Witteveen PO; Suijkerbuijk KPM
Cancer; 2022 Jul; 128(14):2746-2752. PubMed ID: 35439334
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer.
Johns AC; Yang M; Wei L; Grogan M; Spakowicz D; Patel SH; Li M; Husain M; Kendra KL; Otterson GA; Rosko AE; Andersen BL; Carbone DP; Owen DH; Presley CJ
Oncologist; 2023 Aug; 28(8):e625-e632. PubMed ID: 37085156
[TBL] [Abstract][Full Text] [Related]
8. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
9. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
10. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer.
Hayashi-Tanner Y; Polewski PJ; Gaddam M; Fisher NR; Kovacs AJ; Marinier DE
J Geriatr Oncol; 2022 Sep; 13(7):1011-1016. PubMed ID: 35637132
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy accompanied by the G-8 geriatric score: TROD13-003 multicenter study.
Güzelöz Z; Görken İB; Aydın B; Sert F; Yalman D; Parvizi M; Avcı GG; Altınok P; Halis H; Ergen ŞA; Akgün Z; Özkan E; Güney Y; Karaçetin D; Kaydıhan N; Düzova M; Akın M; Uysal B; Erdoğan M; Ellidokuz H; Aksu G; Metcalfe E
J Geriatr Oncol; 2024 Apr; 15(3):101739. PubMed ID: 38492350
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
14. Association between PD-1 inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients.
Li J; Zhang X; Zhou S; Zhou Y; Liu X
Cancer Med; 2023 Apr; 12(8):9272-9281. PubMed ID: 36727563
[TBL] [Abstract][Full Text] [Related]
15. Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.
McLean LS; Lim AM; Bressel M; Thai AA; Rischin D
Drugs Aging; 2024 Mar; 41(3):271-281. PubMed ID: 38446342
[TBL] [Abstract][Full Text] [Related]
16. Effects of comprehensive geriatric assessment-guided interventions on physical performance and quality of life in older patients with advanced cancer: A randomized controlled trial (PROGNOSIS-RCT).
Giger AW; Ditzel HM; Ditzel HJ; Ewertz M; Jørgensen TL; Pfeiffer P; Lund CM; Ryg J
J Geriatr Oncol; 2024 Jan; 15(1):101658. PubMed ID: 37939628
[TBL] [Abstract][Full Text] [Related]
17. Older women are frailer, but less often die then men: a prospective study of older hospitalized people.
Veronese N; Siri G; Cella A; Daragjati J; Cruz-Jentoft AJ; Polidori MC; Mattace-Raso F; Paccalin M; Topinkova E; Greco A; Mangoni AA; Maggi S; Ferrucci L; Pilotto A;
Maturitas; 2019 Oct; 128():81-86. PubMed ID: 31561828
[TBL] [Abstract][Full Text] [Related]
18. Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors.
Welaya K; Loh KP; Messing S; Szuba E; Magnuson A; Mohile SG; Maggiore RJ
J Geriatr Oncol; 2020 Apr; 11(3):523-528. PubMed ID: 31175042
[TBL] [Abstract][Full Text] [Related]
19. Association of frailty and chemotherapy-related adverse outcomes in geriatric patients with cancer: a pilot observational study in Taiwan.
Ho YW; Tang WR; Chen SY; Lee SH; Chen JS; Hung YS; Chou WC
Aging (Albany NY); 2021 Nov; 13(21):24192-24204. PubMed ID: 34747717
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer.
van Holstein Y; Kapiteijn E; Bastiaannet E; van den Bos F; Portielje J; de Glas NA
Drugs Aging; 2019 Oct; 36(10):927-938. PubMed ID: 31317421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
